Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE).
Surasi DS, Eiber M, Maurer T, Preston MA, Helfand BT, Josephson D, Tewari AK, Somford DM, Rais-Bahrami S, Koontz BF, Bostrom PJ, Chau A, Davis P, Schuster DM, Chapin BF; LIGHTHOUSE Study Group. Surasi DS, et al. Eur Urol. 2023 Oct;84(4):361-370. doi: 10.1016/j.eururo.2023.06.018. Epub 2023 Jul 5. Eur Urol. 2023. PMID: 37414702 Free article.
Diagnostic Performance and Safety of 18F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT).
Jani AB, Ravizzini GC, Gartrell BA, Siegel BA, Twardowski P, Saltzstein D, Fleming MT, Chau A, Davis P, Chapin BF, Schuster DM; SPOTLIGHT Study Group. Jani AB, et al. J Urol. 2023 Aug;210(2):299-311. doi: 10.1097/JU.0000000000003493. Epub 2023 Apr 26. J Urol. 2023. PMID: 37126069
Impact of 18F-fluciclovine PET/CT on plans for androgen deprivation therapy in patients with biochemical recurrence of prostate cancer: data analysis from two prospective clinical trials.
Andriole GL, Scarsbrook AF, Savir-Baruch B; LOCATE/FALCON Study Groups. Andriole GL, et al. Among authors: savir baruch b. Urol Oncol. 2023 Jun;41(6):293.e1-293.e7. doi: 10.1016/j.urolonc.2023.04.004. Epub 2023 Apr 29. Urol Oncol. 2023. PMID: 37121865 Free article. Clinical Trial.
Computer assisted interpretation of Tc-99m mercaptoacetyltriglycine diuretic scintigraphy enhances resident performance.
Taylor AT, Fazlur Rahman AKM, Folks RD, Moncayo V, Savir-Baruch B, Plaxton N, Polsani A, Halkar RK, Dubovsky EV, Garcia EV, Manatunga A. Taylor AT, et al. Among authors: savir baruch b. Nucl Med Commun. 2023 Jun 1;44(6):427-433. doi: 10.1097/MNM.0000000000001691. Epub 2023 Apr 10. Nucl Med Commun. 2023. PMID: 37038959 Free PMC article.
Prostate Cancer Imaging with 18F-Fluciclovine.
Savir-Baruch B, Schuster DM. Savir-Baruch B, et al. PET Clin. 2022 Oct;17(4):607-620. doi: 10.1016/j.cpet.2022.07.005. PET Clin. 2022. PMID: 36229104 Review.
177Lu-PSMA Therapy.
Parent EE, Savir-Baruch B, Gayed IW, Almaguel F, Chin BB, Pantel AR, Armstrong E, Morley A, Ippisch RC, Flavell RR. Parent EE, et al. Among authors: savir baruch b. J Nucl Med Technol. 2022 Sep;50(3):205-212. doi: 10.2967/jnmt.122.263814. Epub 2022 Jul 26. J Nucl Med Technol. 2022. PMID: 36215646 Free article. Review.
ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
Love C, Desai NB, Abraham T, Banks KP, Bodei L, Boike T, Brown RKJ, Bushnell DL, DeBlanche LE, Dominello MM, Francis T, Grady EC, Hobbs RF, Hope TA, Kempf JS, Pryma DA, Rule W, Savir-Baruch B, Sethi I, Subramaniam RM, Xiao Y, Schechter NR. Love C, et al. Among authors: savir baruch b. Clin Nucl Med. 2022 Jun 1;47(6):503-511. doi: 10.1097/RLU.0000000000004182. Clin Nucl Med. 2022. PMID: 35507433
45 results